Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.

Journal of psychopharmacology (Oxford, England) - 1 Nov 2006

Yang Jiansong, Jamei Masoud, Heydari Amir, Yeo Karen R, de la Torre Rafael, Farré Magí, Tucker Geoffrey T, Rostami-Hodjegan Amin

Abstract excerpt

The aim of this study was to model the in vivo kinetic consequences of mechanism-based inhibition (MBI) of CYP2D6 by 3,4 methylenedioxymethamphetamine (MDMA, ecstasy). A model with physiologically-based components of drug metabolism was developed, taking account of change in the hepatic content of active CYP2D6 due to MBI by MDMA. Based on the in vitro information, plasma concentration time profiles of MDMA after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cytochrome P-450 CYP1A2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Enzyme Inhibitors

Share to Kidney Diseases

Share to Models, Statistical

Share to Molecular Weight

Source

Identifiers

PMID: 16714321
DOI: 10.1177/0269881106065907

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.PMID 16714321Read ↗

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?Semantic proximity Read ↗

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.Semantic proximity Read ↗

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individualsSemantic proximity Read ↗

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.Semantic proximity Read ↗

Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?Semantic proximity Read ↗

Drug-Drug Interactions via Mechanism-Based Cytochrome P450 Inactivation: Points to Consider for Risk Assessment from In Vitro Data and Clinical Pharmacologic EvaluationSemantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.Semantic proximity Read ↗

Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.Semantic proximity Read ↗

In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone.Semantic proximity Read ↗

Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.Semantic proximity Read ↗

How precise is quantitative prediction of pharmacokinetic effects due to drug-drug interactions and genotype from in vitro data? A comprehensive analysis on the example CYP2D6 and CYP2C19 substrates.Semantic proximity Read ↗

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.